Outcome measures assessed 4 months' after baseline
| Composite outcome | ACR 20%/50%/70% response MDA DAPSA DAPSA 50%/75%/85% response Δ CDAI Δ DAS28 mPASDAS good response Δ mPASDAS |
| Clinical outcomes | Δ SPARCC enthesitis score Δ Dactylitis (number) Δ Number of tender and swollen joints Δ PASI Δ CRP level Δ Physician's global assessment (VAS global) Δ Ultrasonic score Δ AMPS |
| Patient-reported outcomes | Δ VAS-fatigue, Δ VAS-pain, Δ patient VAS-global Δ PSAID Δ BASDAI Δ BASFI Δ SF-36 physical and mental summary scores (PCS, MCS) Δ HAQ-DI scores Δ DLQI Δ WPI Δ GAD-10 Trans-Q score |
Δ, change; ACR, American College of Rheumatology response criteria; AMPS, Assessment of Motor and Process Skills; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; CDAI, Clinical Disease Activity Index; CRP, C reactive protein; DAPSA, Disease Activity Index for Psoriatic Arthritis; DAS28, Disease Activity Score 28; DLQI, Dermatology Life Quality Index; GAD-10, Generalised Anxiety Disorder Self-Assessment Questionnaire; HAQ-DI, Health Assessment Questionnaire Disability Index; MDA, Minimal Disease Activity; mPASDAS, modified Psoriatic Arthritis Disease Activity Score; PASI, Psoriatic Area Severity Index; SF-36, 36- Item Short Form Health Survey; SPARCC, Spondyloarthritis Research Consortium of Canada enthesitis score; Trans-Q, Transition Questionnaire; VAS, Visual Analogue Scale; WPI, Widespread Pain Index.